Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

HIGHLIGHTS

• who: Birgit S. Geurts from the (UNIVERSITY) have published the paper: Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours, in the Journal: (JOURNAL)
• what: The authors aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP).
• how: The study is conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki`s ethical principles for medical research. Besides . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.